Masoud Mokhtarani, M.D.
Chief Medical Officer
Dr. Mokhtarani has extensive experience in clinical development from bench to market with a focus on proof of concept, translational, and early-stage development programs ranging multiple therapeutic areas including neurodegenerative disease, systemic sclerosis, genetic and inherited inborn errors of metabolism, IPF, NASH, and pain. Previously, Dr. Mokhtarani served as Chief Medical Officer of NeuroVia Inc. and Curzion Pharmaceuticals (acquired by Horizon), successfully building clinical development plans for X-linked adrenoleukodystrophy, adrenomyeloneuropathy, and fibrotic diseases. In addition, Dr. Mokhtarani served in executive clinical roles at Hyperion Therapeutics (acquired by Horizon), Limerick Neuroscience, Rinat Neuroscience (acquired by Pfizer), and Immune Tolerance Network. He is a co-inventor of multiple issued patents and an author/co-author of several peer-reviewed publications. Dr. Mokhtarani holds a M.D. from University of Tehran and completed his clinical research Fellowship at UCSF.